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ABSTRACT
Introduction In the Greater Mekong Subregion, adults 
are at highest risk for malaria. The most relevant 
disease vectors bite during daytime and outdoors which 
makes forest work a high- risk activity for malaria. The 
absence of effective vector control strategies and limited 
periods of exposure during forest visits suggest that 
chemoprophylaxis could be an appropriate strategy to 
protect forest goers against malaria.
Methods and analysis The protocol describes an 
open- label randomised controlled trial of artemether- 
lumefantrine (AL) versus multivitamin as prophylaxis 
against malaria among forest goers aged 16–65 years 
in rural northeast Cambodia. The primary objective is 
to compare the efficacy of the artemisinin combination 
therapy AL versus a multivitamin preparation as defined 
by the 28- day PCR parasite positivity rate and incidence 
of confirmed clinical malaria of any species. The sample 
size is 2200 patient- episodes of duration 1 month in 
each arm. The duration of follow- up and prophylaxis 
for each participant is 1, 2 or 3 consecutive 28- day 
periods, followed by a further 28 days of post- exposure 
prophylaxis, depending on whether they continue to visit 
the forest. Analysis will be done both by intention to treat 
and per protocol.
Ethics and dissemination All participants will provide 
written, informed consent. Ethical approval was obtained 
from the Oxford Tropical Research Ethics Committee 
and the Cambodia National Ethics Committee for Health 
Research. Results will be disseminated by peer- reviewed 
open access publication together with open data.
Trial registration number NCT04041973; Pre- result.
INTRODUCTION
In the Greater Mekong Subregion (GMS), 
adults are at highest risk for malaria. The 
most relevant disease vectors bite during 
daytime and outdoors which makes forest 
work a high- risk activity for malaria. The 
absence of effective vector control strategies 
and limited periods of exposure during forest 
visits suggest that chemoprophylaxis could be 
an appropriate strategy to protect forest goers 
against malaria.
In the GMS, a large proportion of malaria 
transmission occurs in forested areas, 
which serve as perpetual sources of trans-
mission.1–5 Studies have demonstrated 
increased risk of malaria among forest 
goers, particularly in men of working age6 7 
although these have largely been restricted 
to small geographical areas. Protecting 
forest goers from Plasmodium infections 
would not only benefit them directly but 
also people residing around their home. 
Malaria elimination efforts which do not 
consider the reinfection risk from forest 
Strengths and limitations of this study
 ► Malaria is a major health problem for forest workers 
in Cambodia. Preventing malaria will provide major 
health as well as socioeconomic benefits for partici-
pants in the first instance and, if rolled out, for forest 
goers more broadly.
 ► The trial intervention was designed together with 
the Cambodian government to be potentially imple-
mentable depending on the results.
 ► Broad engagement with healthcare workers and 
communities in the study area preceded enrolment 
and this is continuing throughout with local health-
care workers and forest goers assisting with running 
the trial including identifying potential participants 
and supporting follow- up.
 ► The trial is open label so participants can know 
which study drug they are taking.
 ► The outcomes are dependent on the incidence of 
malaria during the trial follow- up period.
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workers are unlikely to succeed. However, preventing 
infections in forest workers is a major challenge. The 
biting rhythm and resting behaviour of Anopheles 
dirus reduces the impact of the two most commonly 
employed control measures, long- lasting insecticide 
treated bednets (LLIN) and indoor residual spraying. 
Several studies have also demonstrated poor use of 
personal protection measures against malaria transmis-
sion.8–10 Two factors that increase malaria risk among 
forest workers are the basic character of overnight 
forest accommodation9 and exposure to the Anopheles 
vectors (eg, An. dirus), which tend to bite outdoors in 
daytime. LLIN have a high protective efficacy against 
nocturnal, indoor malaria transmission11 but are less 
protective against daytime, outdoor- biting vectors like 
An. dirus. The improvised housing of forest workers is 
frequently poorly suited to hanging bed nets.12 Imag-
inative interventions such as supplying forest workers 
with insecticide treated hammocks do not address the 
biting rhythm and resting behaviour of the vectors and 
have a disappointing uptake in field studies for a variety 
of reasons including incompatibility with traditional 
sleep arrangements at home or in the forest.10 12 In 
the absence of simple, effective and affordable vector 
control interventions, providing forest goers with effec-
tive antimalarial prophylaxis seems a promising alterna-
tive approach to protect them against malaria provided 
people can be persuaded to take it.13
We propose to evaluate the feasibility and protective 
efficacy of antimalarial prophylaxis during forest work. 
It has been demonstrated in sub- Saharan Africa that 
seasonal malaria chemoprophylaxis (SMC) of children, 
the highest risk group for malaria in tropical Africa, can 
reduce malaria cases by 75%, is cost effective and safe 
and can be given by community health workers. 14 15 We 
propose to provide chemoprophylaxis to forest workers, 
the population group with the highest malaria risk in the 
GMS. In the proposed study, we compare chemoprophy-
laxis with an antimalarial drug, artemether- lumefantrine 
(AL) to a control agent, multivitamins. A recent mass 
drug administration in Cambodia demonstrated that 
dihydroartemisinin (DHA)/piperaquine remains effec-
tive to clear low- density, subclinical Plasmodium falciparum 
infections, but there are increasing treatment failures 
of clinical malaria cases16 and markers of resistance 
to piperaquine in Cambodia are increasing. Although 
artesunate–pyronaridine has recently been introduced 
for treatment in parts of Cambodia, there remain some 
unresolved concerns about potential liver toxicity. 17 
Evidence to date suggests that efficacy of AL remains high 
in Cambodia and it is very well tolerated with an excel-
lent toxicity profile and is thus the preferred potential 
option for prophylaxis by the National Malaria Control 
Programme (NMCP). However, it must be taken with fat 
to maximise absorption. Previously it has been difficult or 
impossible to detect very low- density Plasmodium infec-
tions. It is important to do so as low density and asymp-
tomatic infections are an important source of malaria 
transmission in Southeast Asia. 18 The availability of more 
sensitive PCR methods allows us to detect Plasmodium 
infections with much lower densities. 19 20 By use of PCR, 
we will be able to detect a difference in the prevalence of 
low density, subclinical Plasmodium infections between 
the two study arms in a relatively small sample of study 
participants and will seek to identify all species of human 
malaria including P. falciparum, P. vivax and P. knowlesi.
Chemoprophylaxis of forest workers could protect this 
high- risk group and could reduce or even interrupt trans-
mission in villages. The highly encouraging results of SMC 
in selected regions of sub- Saharan Africa provide hope 
that targeting another high- risk group, forest workers, 
could reduce malaria transmission in Cambodia and the 
wider GMS. In sub- Saharan Africa, children remain the 
main risk group for Plasmodium infections. In Southeast 
Asia, the main risk group are adults working and sleeping 
outdoors hence we propose to provide chemoprophylaxis 
for these adults. A major challenge for this strategy is the 
choice of an appropriate chemoprophylactic regimen in 
the GMS. The chemoprophylactic regimen of choice in 
Africa is sulfadoxine/pyrimethamine (S/P) plus amodia-
quine despite high level resistance against the S/P compo-
nent of the regimen. Similarly, we propose the use of AL, 
a drug whose efficacy remains high in the GMS, unlike, 
for example DHA/piperaquine. 21 The proposed study 
will help to assess the efficacy and feasibility of prophy-
laxis to prevent malaria in forest goers, help to identify 
the optimal regimen and predict its efficacy in reducing 
overall transmission. The proposed study is a critical step 
for future use of chemoprophylaxis to protect forest 
workers in the GMS against malaria.
Proposed activities
AL prophylaxis trial
The study of AL versus a multivitamin preparation will 
be a two- arm randomised open- label comparative study. 
Laboratory assessments of malaria infection at baseline 
and day 28 post forest will be performed blind to treat-
ment allocation and clinical cases during follow- up will 
be recorded.
Activities/outcomes
The main activity proposed is an in vivo clinical assess-
ment of prophylaxis to prevent malaria in 4400 partici-
pant episodes in 50 villages in Stung Treng Province, 
Cambodia. The subjects will be randomised in a one- 
to- one ratio between the artemisinin combination 
therapy (ACT) AL and a multivitamin preparation with 
no antimalarial activity.
The study site has been chosen based on current infor-
mation on incidence of malaria, known predominance of 
malaria among forest goers, presence of an established 
clinical research programme and feasibility to perform 
the proposed research activities.
Efficacy of AL ACT will be assessed through follow- up 
visits 28 days after returning from the forest on completing 
each course of prophylaxis when temperature, symptom 









pen: first published as 10.1136/bm




3Maude RJ, et al. BMJ Open 2021;11:e045900. doi:10.1136/bmjopen-2020-045900
Open access
questionnaires, brief physical examinations and malaria 
parasite PCR, and, in selected individuals, parasite 
genetics will be performed. Episodes of confirmed clin-
ical malaria among study participants at any time point 
between enrolment and follow- up will also be recorded.
All the organisations in this collaboration will work 
closely with local counterparts including the NMCP, non- 
governmental and other relevant organisations. Training 
is an integral part of this collaborative working relation-
ship, and the building of local research capacity is an 
essential component of all research plans.
All research- related activities, from study design, plan-
ning, implementation through to analysis and writing 
of reports will be performed jointly with local counter-
parts. Both on- the- job training and formal training will 
be provided when needed, in particular for good clinical 
practice (GCP) skills.
The close interaction between WHO and its regional 
offices will ensure that new knowledge is disseminated 




To compare the efficacy of the ACT AL versus a multivi-
tamin preparation as defined by the 28- day PCR parasite 
positivity rate and incidence of confirmed clinical malaria 
of any species.
Secondary objectives
1. To compare the efficacy of the ACT AL versus a mul-
tivitamin preparation as defined by the 28- day, 56- day 
and 84- day PCR parasite positivity rate and incidence 
of confirmed clinical malaria for each species.
2. To quantify the impact of the ACT AL as prophylaxis 
for forest goers on overall malaria transmission using 
mathematical modelling.
3. To assess the impact of AL prophylaxis on the spread 
of genetic markers of artemisinin (such as Kelch13 mu-
tations) and partner drug resistance.
4. To obtain data on the place of residence, work, recent 
travel history and risk behaviours of forest goers in or-
der to improve the understanding of high- risk groups, 
locations of malaria transmission and possible routes 
spread of malaria and artemisinin resistance.
5. To explore the duration, location and purpose of indi-
vidual forest visits.
6. To obtain detailed data and Global Positioning Sys-
tem (GPS) mapping on a subset of participants and 
their peers relating to the behaviours and risk factors 
associated with malaria infection in order to improve 
understanding of local malaria transmission among 
forest goers.
7. To determine the prevalence of asymptomatic Plasmo-
dium infections in high- risk populations at varying sea-
sonal time points.
8. To determine the prevalence of other infectious diseas-
es that affect the study population.
Trial design
Study sites
The study will take place at up to 50 villages in selected 
malaria endemic districts in Stung Treng Province, 
Cambodia. As the malaria situation in this area is dynamic, 
the villages will be identified prior to the start of the 
trial from analysis of up to date malaria incidence from 
passive surveillance collected by the Cambodia National 
Center for Parasitology, Entomology and Malaria Control 
(CNM). The rationale for choosing these areas include 
high forest cover and ongoing malaria transmission 
among forest goers. Malaria transmission in this area is 
generally low but varying over time.
Summary of trial design
An open- label randomised parallel group superiority trial 
among forest goers comparing the ACT AL with a multi-
vitamin with no antimalarial activity to evaluate the effi-
cacy of prophylaxis, and to better understand high- risk 
groups and locations of malaria transmission. Follow- up 
will be for 1–3 consecutive periods of 28 days depending 
on whether the participant continues to visit the forest.
Study duration
The recruitment phase of the study is expected to last 
12 months. Training and community sensitisation will 
precede study execution for 3 months. Data management 
and analysis, sample analysis (PCR, parasite genetics), 
mathematical modelling and report writing are expected 
to take about 5 months. The total time to complete the 
study will be about 20 months.
Primary and secondary endpoints
Composite primary endpoint
1. 28- day PCR positivity rate* of Plasmodium infections 
of any species and/or
2. Proportion of participants with confirmed clinical ma-
laria of any species reported between day 0 and day 28.
Secondary endpoints
1. 28- day, 56- day and 84- day PCR Plasmodium positivity 
rate for each Plasmodium species.
2. Proportion of participants with confirmed malaria 
reported between day 0 and day 28 for each species.
3. Description of epidemiological situation of malaria 
in the study areas from passive surveillance data.**
4. Prevalence of Kelch13 mutations and other genetic 
markers of antimalarial drug resistance of known 
functional significance.
5. Incidence of adverse events (AEs) and serious ad-
verse events (SAEs) by study arm during the course 
of prophylaxis.
6. Data on the place of residence, work, recent travel 
history and mobile phone use.
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7. Detailed data and GPS mapping on a subset of partic-
ipants and their peers relating to the behaviours and 
risk factors associated with malaria infection.
8. Overall prevalence of Plasmodium at baseline, strati-
fied by season and risk factors.
9. Day 0, 28, 56 and 84 capillary blood levels of 
lumefantrine.
10. Prevalence of serological diagnostic markers of other 
infectious diseases.
*PCR positivity rate as determined from the proportion 
of blood samples that were PCR positive.
**This will include the number of cases per village and 
demographics of those cases.
Trial participants
Overall description of trial participants
Male and non- pregnant female participants aged between 
16 years and 65 years planning to visit the forest within 
72 hours are the target study population. The upper age 
limit was chosen as people over 65 years in the study area 
rarely travel to the forest and are at low risk of malaria. 
All pregnant women will be excluded as a conservative 
measure to minimise risk because of insufficient evidence 
for safety of AL in the first trimester together with frequent 
uncertainty about the stage of pregnancy, as well as lack 
of consensus about the required dose in pregnancy. All 
study participants must meet the applicable inclusion and 
exclusion criteria.
Inclusion criteria
1. Male or female, adults aged between 16 and 65 years.
2. Planning to travel to the forest within the next 72 hours 
and stay overnight.
3. Written informed consent.
4. Willingness and ability of the participants to comply 
with the study protocol for the duration of the study.
Exclusion criteria
1. For females: known pregnancy or breast feeding.
2. Participants who have received artemisinin or a deriva-
tive or an ACT within the previous 7 days.
3. History of allergy or known contraindication to arte-
misinins, lumefantrine or multivitamins.
4. Documented or claimed history of cardiac conduction 
problems.
5. Severe vomiting or diarrhoea on the day of screening.
6. Signs/symptoms of clinical malaria (febrile or history 
of fever in the previous 24 hours) confirmed by rapid 
diagnostic test (RDT).
Procedures
Study procedures will be performed according to the 
schedule of assessments (online supplemental file 1). 
This will require that participants are followed up every 
28 days for up to three periods on completion of a course 
of prophylaxis. Enrolment will be done by trained trial 
staff.
Informed consent
Prior to the start of enrolment we will conduct commu-
nity mobilisation and sensitisation activities in each 
village community where the trial will recruit participants. 
During the trial, the participant (or witness if illiterate) 
must personally sign and date the latest approved version 
of the informed consent form before any study specific 
procedures are performed. Written and verbal versions 
of the participant information and informed consent in 
the local language will be presented to the participants 
by trained study staff detailing no less than: the exact 
nature of the study; the implications and constraints of 
the protocol; and the known side effects and any risks 
involved in taking part. It will be clearly stated that partici-
pation is voluntary and that the participant is free to with-
draw from the study at any time for any reason without 
prejudice to future care, and with no obligation to give 
the reason for withdrawal.
The participant will be allowed as much time as possible 
to consider the information and take the opportunity to 
question the investigator, or other independent parties 
to decide whether they will (or allow his/her charge to) 
participate in the study. Written informed consent will 
then be obtained by means of participant dated signature 
or thumb print (if unable to write) and dated signature 
of the person who presented and obtained the informed 
consent. Examples of the patient information sheet and 
consent form for this study are provided in English in 
online supplemental files 2 and 3, respectively.
A copy of the signed informed consent document(s) 
will be given to the participants.
Children aged 16 to <18 years will be required to sign 
the latest approved version of the written informed assent 
form in addition to their parent or guardian signing a 
consent form.
Screening, eligibility and baseline assessments
Participants who present at the participating sites will be 
screened to assess eligibility. Full consent will be obtained 
before any enrolment procedures are conducted. It will 
be made clear from the outset that refusal to participate 
will not jeopardise subsequent antimalarial treatment 
(if applicable). A screening log will be kept. As detailed 
below, participants may be enrolled a maximum of three 
times during the study period. People that cannot return 
for follow- up as per the schedule will not be enrolled. 
Known pregnancy will be identified by self reporting.
Demographics and medical history
Basic demographic and epidemiological data (e.g. sex, 
age, weight, address, bed net use, malaria risk factors, 
travel history, prior malaria episodes, prior treatment and 
previous participation in this or previous studies), and a 
full medical history will be recorded by the study staff.
Physical examination and vital signs
Brief physical examination and vital sign will be 
conducted by a qualified study team member. Weight and 
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temperature will be documented. A symptom question-
naire will be performed.
Drug history
All prescribed or over- the- counter and traditional anti-
malarial medications used within the last 7 days will be 
recorded. Any drug allergies will be recorded.
Clinical malaria
Participants who are screened and are found to be febrile 
or have a current history of fever will not be enrolled (as 
per exclusion criteria) but will be tested for malaria and, 
if positive, given antimalarial treatment by the village 
malaria worker or local clinic. All this will be done in 
accordance with the current national malaria treatment 
guidelines in Cambodia. Individuals treated for malaria 
in this way will not be enrolled in the study as per the 
exclusion criteria. Such individuals may be enrolled later 
following recovery provided they meet the inclusion and 
exclusion criteria.
Randomisation, allocation and blinding
Participants who fulfil all the inclusion criteria and have 
none of the exclusion criteria will be randomised 1:1 
to one of the two treatment arms according to a rando-
misation schedule. Randomisation will be in permuted 
blocks of size that will be determined by the trial statisti-
cian and the block size will not be revealed to the inves-
tigating team. Randomisation will be stratified by village 
and villages combined for the analysis. Allocation will 
be done by trained study staff drawing the next sequen-
tial numbered opaque envelope (or other equally reli-
able randomisation administration procedure), which 
contains the study number and treatment allocation.
The participants will be assigned a study arm through a 
computer- generated randomisation schedule. Individual, 
sealed and sequentially numbered envelopes will be 
provided for each trial site with one envelope per partici-
pant, indicating the treatment allocation.
This is an open- label study so the blinding of inves-
tigators and participants is not applicable. However, 
the randomisation procedure allows for adequate drug 
allocation concealment before envelopes are opened. 
All laboratory investigations will be performed without 
knowledge of the treatment allocation.
Blood sampling on study enrolment
On study enrolment, immediately before drug adminis-
tration, blood will be collected for the following:
1. Parasite PCR (up to 1 mL).
2. Storage for later identification of other causes of fever 
(2 mL).
In case of difficulties with venipuncture on enrolment 
(eg, due to dehydration, suitably qualified staff not avail-
able in the village) or loss of cold chain during transport 
from remote villages, three dried blood spots will be 
collected on enrolment for PCR and the other sample 
collected at follow- up.
Study drug administration
Overview of drug regimens
ACT arm Multivitamin arm
Artemether- lumefantrine × 
3 days followed by 1 day per 
week, two times per day
Multivitamin × 3 days 
followed by 1 day per 
week, once daily
Participants will be treated with weight- based doses 
according to the schedule in online supplemental file 1.
The study drugs will be administered by trained study 
staff.
If the participant vomits within half an hour after intake 
of the antimalarial drugs, the dose will be repeated. If 
vomiting occurs between half and 1 hour, half of the dose 
will be repeated. If vomiting occurs more than 1 hour 
after drug administration, no repeat dosing will be done. 
Repeat doses will be recorded on the case report forms 
(CRFs). If vomiting within 1 hour occurs more than one 
time, no repeat dosing is allowed. The participant will 
then be treated at the discretion of the investigator.
The prophylaxis will start with a 3- day course of two 
times per day AL. This will be followed by two doses 
8 hours apart on 1 day per week during the time that the 
person is travelling in the forest and for 4 weeks after 
leaving the forest.
Follow-up
Participants will be asked to return for a follow- up assess-
ment any time from 28 to 35 days after commencing 
prophylaxis. Twenty- eight days was chosen as the upper 
limit of the time from infection to detectable parasites in 
the blood. Ongoing studies in the area found the dura-
tion of forest visits varied from a day to several weeks, with 
very few people being away for more than 28 days. This 
will be regardless of the duration of their visit to the forest 
or the number of times they visit it in that period. At this 
assessment, they will be interviewed about how long they 
spent in the forest, where they went, why, who they trav-
elled with and about risk factors for infection. Brief phys-
ical examination, vital signs and symptom questionnaire 
will be performed. They will also be asked to report any 
diagnostic tests and/or treatment for malaria during the 
preceding 28–35 days.
Blood sampling at follow-up
At each follow- up visit, the following blood will taken:
All individuals:
 ► Parasite PCR (up to 1 mL).
In those from whom sufficient blood could not be 
collected at baseline:
 ► Storage for later identification of other causes of fever 
(2 mL).
From minimum 100 randomly selected individuals:
 ► Lumefantrine level (0.2 mL).
In those with confirmed clinical malaria at any time point 
between enrolment and follow- up:
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 ► Dry blood blots (0.4 mL, 3 spots) collected on filter 
papers for:
Parasite PCR and DNA genotyping for genetic markers 
of antimalarial resistance.
Parasite whole genome sequencing and barcoding to 
identify geographical origin of parasites and compare 
genotypes to identify persistent infections.
In individuals who are planning to return again to the 
forest within the following 28 days after the follow- up 
visit, they will be asked to continue their weekly proph-
ylaxis according to the original treatment allocation on 
enrolment. They will then be asked to return for a second 
follow- up visit a further 28–35 days later when the above 
procedure will be repeated. This will be repeated one 
more time. If the person cannot be followed up within 
the scheduled period, for example, because they do not 
return from the forest in time, then they will be followed 
up at the first opportunity and this will be recorded in 
the CRF.
Thus individuals may take prophylaxis continuously 
for a maximum of three periods of 28–35 days in the 
forest plus 4 weeks after returning totaling 112 days. The 
choice of study medication for each individual will follow 
the initial assignment on enrolment throughout the 
follow- up period.
In those who do not declare an intention to return to 
the forest within 28 days at any follow- up visit, no further 
follow- up visits will be offered at that time but they will be 
asked to complete 4 weeks of prophylaxis following their 
last day in the forest as post- exposure prophylaxis.
Individuals who have been enrolled in the study may 
be enrolled into the study up to two more times during 
the 12 months study period only if a minimum period of 
28 days (4 weeks) has elapsed following their last dose of 
prophylaxis. Thus they can be enrolled in the study up to 
three times. If an individual is enrolled again in this way, 
they will be re- randomised following the same procedure 
as enrolment. The rationale for this re- enrolment was 
that malaria transmission and forest travel are seasonal 
at this location and this allows detection of malaria posi-
tive episodes in people who continue to visit the forest 
throughout the year while minimising the period of 
follow- up for the majority of people who visit the forest 
only during a particular season; in addition, it allows a 
wash- out period between episodes of taking prophylaxis.
Time windows
The time- window for the follow- up visits is 28–35 days. If 
a participant does not attend, the study team will try to 
locate the participant and conduct the necessary exam-
inations and tests.
Additional visits
Participants presenting to the village malaria worker, 
mobile malaria worker or clinic with a fever or other 
symptoms at any time after enrolment that is not a sched-
uled study follow- up visit will be assessed and treated by 
the healthcare workers in the local healthcare system as 
per routine clinical practice in Cambodia.
On enrolment, participants will be encouraged to 
attend a village malaria worker or government clinic for 
the assessment of fever or other symptoms and to report 
this to the study team as soon as possible. Information on 
these healthcare encounters including malaria test result 
and treatment will be recorded in the study CRF.
Clinical malaria during follow-up
Participants who have an episode of confirmed clinical 
malaria at any time after enrolment up to the last follow- up 
visit and for 1 month afterwards will have blood taken for 
parasite genetic analysis. As clinical malaria at follow- up is 
part of the composite primary endpoint, and the partic-
ipants and field staff will not be blinded as to study arm, 
there is potential for bias if, for example, people in the 
AL arm choose not to attend for a malaria test. However, 
extensive efforts will made through community engage-
ment and individual counselling to advise participants 
against this.
Blood volumes
The blood volumes for the protocol mandated tests are 
as follows:
1. PCR: up to 1 mL.
2. Lumefantrine level: 0.2 mL.
3. Dried blood spots for parasite genetics: 0.4 mL.
4. Storage for serology at baseline 2 mL.
Maximum blood volumes are presented below for adults 
for the maximum of three periods (84 days) of follow- up. 
The maximum blood volume is the total amount taken 
if the participants returns for follow- up on three consec-
utive occasions and had all blood samples taken. The 
maximum blood volume will be approximately 10.2 mL 
(less than 10% of total blood volume taken over 8 weeks 
as recommended by WHO- Bulletin of the World Health 
Organization 2011:89:46–53).
Allowing for the possibility that we may need to repeat 
blood tests, we may add 10.2 mL to these estimated 
maximum blood volumes.
Blood samples collected from this study will be stored 
no longer than 10 years using codes assigned by the study 
team or their designee(s). Access to research samples will 
be limited using either a locked room or a locked freezer.
Analysis of blood samples
Parasite PCR
This is required for the primary study objective. Blood 
samples will be analysed in the Molecular Tropical Medi-
cine Laboratory, Bangkok, Thailand using PCR to identify 
which individuals have malaria parasites of any species. 
It is anticipated that results will be available around 3–6 
months after collecting each sample, thus they will not 
be used to guide antimalarial treatment at the time of 
testing. The study teams will be informed which samples 
were positive for malaria and they will follow- up positive 
participants to conduct a brief clinical assessment. Any 
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individuals who are symptomatic will be referred to the 
village malaria worker or clinic for testing and treatment. 
The laboratory will be blinded to the study arm of the 
patient.
Parasite genetic analysis
Blood samples (dried blood spots) for parasite genetic 
analysis will be obtained and stored from all subjects 
recruited with subject’s consent. In individuals in whom 
parasites are found by PCR, samples will be processed for 
parasite genetic analysis. Genetic samples (in the form of 
dried blood spots or extracted DNA) will be stored (for a 
maximum of 10 years) at the Molecular Tropical Medicine 
Laboratory, Bangkok, Thailand. In those with confirmed 
clinical malaria, parasite genotyping will be performed 
at the Wellcome Trust Sanger Institute in Hinxton, UK 
or other suitable laboratory using a set of informative 
single nucleotide polymorphisms (SNPs) selected from 
whole genome sequencing. The subject will be asked 
for consent for this transfer during the initial informed 
consent process. A material transfer agreement will be 
in place if required before any samples are shipped. The 
results of the parasite genotyping will not be reported 
back to the subjects. This analysis will only be done for 
those with confirmed clinical malaria as it is anticipated 
that there will be insufficient genetic material in samples 
taken from those with asymptomatic infection due to the 
low parasite burden in these individuals.
Lumefantrine level
Blood samples for lumefantrine level will be taken at 
follow- up visits from a minimum of 100 randomly selected 
participants, where logistically possible, to assess adher-
ence with the study drugs. These will be analysed in the 
Pharmacology Laboratory at Mahidol- Oxford Tropical 
Medicine Research Unit (MORU) in Bangkok, Thailand.
Serology
Among those who specify by written consent, the serology 




AL is currently available as standard tablets containing 
20 mg artemether and 120 mg of lumefantrine in a fixed- 
dose combination formulation. It is included in this 
formulation on the WHO Model List of Essential Medi-
cines. 22
Target dose/range
The AL is administered as a two times per day dose for 
3 days for a total of six doses (an initial dose, second dose 
after 8 hours and then two times per day—morning and 
evening—for the following 2 days) followed by two times 
per day once a week according to the treatment schedule 
in online supplemental file 1.
Multivitamin
The multivitamin preparation will be HEXA CMP 
(Chemephand Medical) or suitable equivalent alterna-
tive administered as a once daily dose using the treatment 
schedule in online supplemental file 1. This multivitamin 
does not contain any compound with antimalarial activity. 
Its components are: vitamin A: 5000 USP units, vitamin 
D: 400 USP Units, ascorbic acid: 75 mg, thiamine mono-
nitrate: 2 mg, riboflavin: 3 mg and niacin amide: 20 mg. 
A multivitamin was chosen because a placebo was not 
available from the manufacturer for this trial. The multi-
vitamin has no effect on malaria, is safe, is acceptable to 
the community and is easily available at the study site. 
Providing a medication to all participants makes it easier 
to explain the study in a way that is socially acceptable, 
and has potential to discourage the sharing of study drugs 
by participants in the two study arms.
Storage of study drugs
All efforts will be made to store the study drugs in accor-
dance with the manufacturers' recommendations in a 
secure area. This may be difficult at some sites where air- 
conditioned storage rooms are not available. The ACT 
should be stored between 15°C and 30°C (59°F–86°F).
Where this is not possible and monitored storage condi-
tions do not meet the recommendations, the artemisinin- 
derivatives and partner drug content of batches of ACT 
will be retested at the end of the study.
Compliance with study drugs
Study drugs will be administered as directly- observed- 
therapy (DOT) on the first day. Where possible, study 
drugs will also be administered as DOT on days 2 and 
3. Where DOT is not possible, the participant will be 
contacted by the study team by telephone or in person to 
ensure they take the second and third days of medication 
and to ensure they follow the correct procedure in case 
of vomiting. If the participant vomits, and is re- dosed; 
this will be recorded in the CRF. If vomiting within 
1 hour occurs again after retreatment, no repeat dosing 
is allowed. All drug doses will be recorded in the CRF. To 
maximise adherence to the study medication, the study 
will be preceded by a period of community sensitisation 
and engagement including information sessions on the 
importance of taking all doses of medication. The partic-
ipants will be requested to take each dose with food to 
maximise absorption of the lumefantrine.
Accountability of the study treatment
All movements of study medication will be recorded. Both 
study medication of individual participant and overall 
drug accountability records will be kept up to date by the 
study staff.
Concomitant medication
Throughout the study, investigators may prescribe 
concomitant medications or treatments deemed neces-
sary (eg, antipyretics or anti- emetics) to provide adequate 
supportive care except for antibiotics with antimalarial 
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activity unless unavoidable (eg, doxycycline, azithro-
mycin). If these are required, the participants will be kept 
in the study and this will be noted as a protocol deviation. 
Anti- emetics should not be prescribed as a prophylaxis if 
no nausea or vomiting is present.
Antimalarials for symptomatic, confirmed malaria infec-
tions will be prescribed as described above. Any medica-
tion, other than the study medication taken during the 
study will be recorded in the CRF.
Epidemiological data on place of residence, work, travel 
history and malaria risk
In order to have a greater understanding of the possible 
sites of malaria transmission, and to relate genetic diver-
sity to geographical location, participants will be asked a 
short set of questions on their place of residence, place of 
work and their history of travel plus possible risk factors 
for malaria. This is to obtain a detailed understanding of 
the behaviours and risk factors for malaria infection. We 
will collect GPS coordinates of the places of residence 
of all participants. In a subset of participants, GPS coor-
dinates will be collected for their travel patterns during 
follow- up including place of work, forests, forest camps, 
farms or plantations to identify places where their infec-
tion may have occurred. The size of this subset will be 
determined by the availability of GPS devices with the 
number being limited to 50 participants at any one time. 
The GPS devices will be offered to unselected consecu-
tive trial participants whenever they are available, being 
returned on completion of follow- up for that individual. 
We will collect all available local malaria treatment 
records to describe how the study population compares to 
the overall population who receive treatment for malaria 
and this will allow us to better understand local malaria 
epidemiology and transmission patterns. All personal 
information will be anonymised so that no individual can 
be identified from their treatment records, through inter-
views or from mapping data.
Malaria incidence data
Passive surveillance data from all available sources for 
the study province collected by CNM will be analysed to 
identify any changes in malaria incidence rate in study 
villages before, during and after the study where AL 
prophylaxis was administered compared with non- study 
villages.
Enrolled participants who experience an episode of 
confirmed clinical malaria during follow- up will be linked 
back to their individual case records to quantify the inci-
dence of clinical malaria in each study arm.
Analysis
PCR for parasites
PCR will be used to identify which individuals have para-
sites at enrolment (prior to taking the study medicine) 
and at each follow- up visit and is required for the primary 
study objective.
Parasite genetics
Parasite DNA will be used for genomic studies including 
but not limited to parasite species confirmation, microsat-
ellite typing to identify parasite clones and SNPs typing/
whole genome sequencing to generate data for studies of 
the geographic origins of the parasites.
Lumefantrine levels
Lumefantrine levels will be used to assess adherence in a 
random sample of study participants.
Serology
The serology sample will be used for anonymised inves-
tigation of the prevalence, incidence, association with 
fever, and risk factors for other common infectious 
diseases affecting the study population. Samples will be 
stored for later analysis.
Retention, discontinuation/withdrawal of participants from 
the study
All efforts will be made to retain as much data as possible. 
The main strategy that is being re- enforced for data 
retention includes study staff reminding participants of 
the upcoming data collection. This will be emphasised 
during management training. However, each participant 
has the right to discontinue the study drug or the study at 
any time. Data accrued up until the time of discontinua-
tion will be used in the analysis.
In general, the investigators will be required to make 
every effort to perform the study procedures until 
completion of follow- up (maximum three visits over 84 
days), including in the following situations:
 ► Significant non- compliance with treatment regimen 
or study requirements.
 ► An AE which requires discontinuation of the study 
medication or results in inability to continue to 
comply with study procedures.
 ► Disease which requires discontinuation of the study 
medication or results in inability to continue to 
comply with study procedures.
 ► Loss to follow- up (every attempt should be made to 
re- contact the participant).
However, the investigator may discontinue participa-
tion in the study of a participant if he or she considers it 
necessary.
In addition, the participants always have the right to 
withdraw consent in writing or verbally.
The reason for withdrawal or discontinuation, if avail-
able, will be recorded in the CRF. If the study drug or 
participation in the study is discontinued due to an AE, 
the investigator will arrange for follow- up visits at least 
until the AE has resolved or stabilised.
If a participant does become pregnant during partici-
pation in the study, they will be withdrawn from the study 
immediately on it being reported to the study team. Any 
pregnancy must be reported to the principal investigator 
(PI) within one working day of awareness. The PI must 
take all reasonable efforts to discover the outcome of the 
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pregnancy and fill out the pregnancy form. If there is a 
congenital abnormality or a stillborn baby, this needs to 
be reported as an SAE.
Source data
Source documents are original documents, data, and 
records from which participants’ CRF data are obtained. 
These include, but are not limited to, village malaria and 
clinic records (from which medical history and previous 
and concomitant medication may be summarised into the 
CRF), clinical and office charts, laboratory and pharmacy 
records, diaries, microfiches, radiographs and CRFs.
CRF entries will be considered source data if the CRF 
is the site of the original recording (e.g. there is no other 
written or electronic record of data). In this study, the 
CRF will be used as the source document for most of the 
data points.
All documents will be stored safely in confidential 
conditions.
Safety reporting
This trial will use drugs that have either been registered 
or evaluated extensively. To add to the evidence base for 
safety of AL as prophylaxis, we will record and review all 
AEs and SAEs that are reported to occur in the study.
A symptom questionnaire will be performed on enrol-
ment and at each subsequent follow- up visit to the 
healthcare centre, to aid in the identification of AEs. 
In addition, enrolled individuals will be encouraged to 
promptly report any unexpected symptoms or illnesses 
between follow- up visits to the study team.
The investigator is responsible for the detection and 
documentation of events meeting the criteria and defini-
tion of an AE or SAE, as provided in this protocol.
All SAEs and AEs will be promptly documented from 
the moment of drug administration in the study to 
discontinuation of the participant from study participa-
tion. Any events occurring between screening and drug 
administration will be considered as baseline, preexisting 
conditions.
All AEs must be recorded in the AE/SAE CRF. To avoid 
colloquial expressions, the AE should be reported in stan-
dard medical terminology. Whenever possible, the AE 
should be evaluated and reported as a diagnosis rather 
than as individual signs or symptoms. If a definitive diag-
nosis is not possible, the individual symptoms and signs 
should be recorded. Whenever possible, the aetiology of 
the abnormal findings will be documented on the CRF. 
Any additional relevant laboratory results obtained by 
the investigator during the course of this study will be 
recorded on the CRF.
If the event meets the criteria for ‘serious’, the SAE 
must be reported to the PAL- Cambodia safety team within 
24 hours of the time that the event was identified. If 
further data are required, additional documentation can 
be submitted. All SAEs must be followed until resolution, 
or until the SAE is deemed permanent or leads to death.
Samples will be shipped for PCR to a molecular labo-
ratory where they will be analysed in batches. Quality 
control results will be available approximately 3–6 months 
from the time of collection. The list of positive tests will 
be returned to the field sites. If a participant is found 
to have a Plasmodium infection, and has not already 
received antimalarial treatment subsequent to the sample 
being collected, then these individuals will be contacted 
by a local health worker, and if a participant reports fever 




An AE is any undesirable event or clinical deterioration 
that occurs to a study participant during the course of 
the study; that is, from the time of administration of 
study drugs until study ends (i.e. until the follow- up visit) 
whether or not that event is considered related to the 
study drugs, or to a concomitant drug or procedure: for 
example,
1. Any unfavourable and unintended symptom.
2. Physical sign.
3. Abnormal laboratory result.
4. An illness.
Any new clinical sign or clinical deterioration that 
occurs between signing the consent form and the admin-
istration of study drugs is not an AE. This information 
will be recorded in the medical records, as a pre- existing 
condition.
Serious adverse event
An SAE is an AE that:
 ► Results in death.
 ► Is life- threatening that is, the participant was at risk of 
death at the time of the AE.
 ► Requires in participant hospitalisation or prolonga-
tion of existing hospitalisation.
 ► Results in persistent or significant disability/
incapacity.
 ► Is a congenital anomaly/birth defect.
 ► Any other significant medical condition.
All of the above criteria apply to the case as a whole and 
should not be confused with the outcomes of individual 
reactions/events. More than one of the above criteria 
can be applicable to the one event. Important medical 
events that may not be immediately life- threatening or 
result in death or hospitalisation may be considered an 
SAE when, based on appropriate medical judgement, 
they may jeopardise the participant or require medical 
or surgical intervention to prevent one of the outcomes 
listed in the definition above. Examples of such medical 
events include allergic bronchospasm requiring inten-
sive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in hospitalisa-
tion, or development of drug dependency or drug abuse.
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Reporting procedures for SAEs
All SAEs must be reported by the site investigator to the 
Study PI and PAL- Cambodia safety and medical monitor, 
within 1 day of his or her awareness of the SAE. The SAE 
report, should be emailed to the email  paltrial@ tropmedres. 
ac.
Further reports should be submitted, if required, until 
the SAE is resolved.
The site investigator must also report the SAEs to the local 
ethics committee in accordance with local requirements.
Evaluating AEs and SAEs
Assessment of intensity
Each AE will be graded according to the Common 
Terminology Criteria for Adverse Events (CTCAE) V.5.0 
November 2017.
If an AE is not listed in the CTCAE table, the investigator 
will assess the severity using the following guidelines:
1=Mild; asymptomatic or mild symptoms; clinical or 
diagnostic observations only; intervention not indicated.
2=Moderate; minimal, local or noninvasive intervention 
indicated; limiting age appropriate instrumental ADL.*
3=Severe or medically significant but not immediately 
life- threatening; hospitalisation or prolongation of hospi-
talisation indicated; disabling; limiting self care ADL**
4=Life- threatening consequences; urgent intervention 
indicated.
5=Death related to AE.
Activities of Daily Living (ADL).
*Instrumental ADL refer to preparing meals, shopping 
for groceries or clothes, using the telephone, managing 
money and so on.
**Self care ADL refer to bathing, dressing and 
undressing, feeding self, using the toilet, taking medica-
tions and not bedridden.
Clarification of the difference in meaning between ‘severe’ and 
‘serious’
The term ‘severe’ is often used to describe the intensity 
(severity) of a specific event (as in mild, moderate or 
severe myocardial infarction); the event itself, however, 
may be of relatively minor medical significance (such as 
severe headache). This is not the same as ‘serious’, which 
is based on the outcome or criteria defined under the SAE 
definition. An event can be considered serious without 
being severe if it conforms to the seriousness criteria, simi-
larly severe events that do not conform to the criteria are 
not necessarily serious. Seriousness (not severity) serves 
as a guide for defining regulatory reporting obligations.
Assessment of relatedness
The investigator is obligated to assess the relationship 
between study drug and the occurrence of each AE/SAE 
using the following categories of relatedness:
1. Definite: clear- cut temporal association.
2. Probable: clear- cut temporal association, with im-
provement on drug withdrawal, and not reasonably 
explained by the participant’s known clinical state or 
other aetiology.
3. Possible: less clear temporal association; other aetiolo-
gies are possible (other possible aetiologies should be 
recorded on the CRF).
4. Not related: no temporal association with the study 
drug; assessed as related to other aetiologies such as 
concomitant medications or conditions, or partici-
pant’s known clinical state.
The investigator will provide the assessment of causality 
as per the AE/SAE data collection tool.
Outcome
The investigator will follow- up the AE and SAE until reso-
lution or until no further medically relevant information 









The target population for this study will be adult Cambo-
dians who work and sleep in the forest (farmers, collect 
forest goods, hunting and so on). Two thousand two 
hundred study participant episodes are required in each 
arm to have sufficient power to detect a statistically signif-
icant difference between the treatment arm and a control 
arm. An episode is defined as a follow- up period of 28 days 
with each enrolled individual contributing 1, 2 or 3 episodes. 
The estimate of the required sample size is complicated by 
the scarce data on P. falciparum incidence in forest workers.
Formally, we anticipate that the risk of being P. falci-
parum positive without receiving prophylaxis will be 
around 5%. A total of 1605 participant- episodes per 
arm are enough to detect a difference of at least 40% in 
the proportion of episodes with a P. falciparum positive 
result as defined by the 28- day PCR parasite positivity 
rate, that is from 5% positivity in participants without 
receiving antimalarial prophylaxis (ie, multivitamin) to 
3% positivity in participants receiving AL prophylaxis. 
This has been estimated with 80% power and 5% signifi-
cance level. However, we also anticipate that we will likely 
observe multiple episodes being recruited into the study 
that can reduce power of the study if not accounted for. 
To compensate for the multiple episodes and any losses 
to follow- up, we plan to recruit approximately 600 (ie, 
595) additional episodes in each group on top of the 
required 1605 single episodes. This gives an additional 
27% episodes to account for the multiple episodes and 
losses to follow- up. Thus, the overall sample size will be 
4400 episodes (ie, 2200 episodes in the treatment arm 
and 2200 episodes in the control arm). The sample size 
calculations have been performed in Stata V.15.
Statistical analyses
The main analysis strategy for the primary outcome will 
be the intention to treat (ITT) principle followed by the 
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per protocol (PP) analysis. Thus, we will first analyse the 
ITT population in which all participants recruited in 
the trial will be included in the analysis according to the 
randomisation arm irrespective of what they actually got. 
These ITT analyses will be followed by the analysis of the 
PP population in which participants who did not adhere 
to the protocol will be excluded from analysis.
The composite primary endpoint will be analysed as 
follows. For 28- day PCR Plasmodium positivity and para-
site positive clinical episode rate analysis, each arm will be 
summarised using crude proportions and binomial exact 
95% CIs. The risk differences in Plasmodium positivity 
between AL versus multivitamin will be reported along 
with the corresponding 95% CIs. Robust standard errors 
will be used to handle multiple episodes. These analyses 
will be complemented by the use of the crude Kaplan- 
Meier estimates of cumulative PCR Plasmodium posi-
tivity and parasite positive clinical episode probabilities 
as recommended by WHO. The incidence of confirmed 
clinical malaria between day 0 and day 28 analysis will 
be modelled using the mixed effects Poisson regression 
model to obtain incidence rate ratios comparing AL 
versus multivitamin arms. The mixed effects models will 
take into account the correlation of multiple episodes 
from the same participant. Tests of significance will 
be performed at 5% significance level. Analysis of all 
endpoints will be described in detail in a Statistical Anal-
ysis Plan finalised prior to locking the database. A brief 
overview is given below.
Proportions
These will be compared using chi squared or Fisher’s 
exact test, as appropriate. Crude proportions will be 
calculated with the exact 95% CIs, where relevant.
Continuous data
These will be summarised by medians (IQR, ranges) and 
means (SD, 95% CIs), as appropriate, and will include 
the parasite counts and laboratory parameters. Compari-
sons of continuous data will be assessed using the paired/
unpaired t- tests or the signed rank/Mann- Whitney U 
tests, as appropriate.
Safety analysis
Safety analyses will be based on the whole population that 
get administered the study drug. Safety and tolerability of 
ACT versus multivitamin will be assessed by comparing the 
frequency (%) of AEs and SAEs, with particular attention 
to abdominal pain and appetite perturbation, using the 
Fisher’s exact test. Safety data will be presented in tabular 
and/or graphical format and summarised descriptively. Any 
clinically relevant abnormalities or values of potential clini-
cally concern will be described. Participants will be analysed 
according to an ITT and a PP method where appropriate.
Handling of missing data
For analyses of proportions, missing outcomes will be 
imputed using plausible values. For example, worst- case 
scenario may be deemed appropriate and in that case 
sensitivity analysis will be performed with the best- case 
scenario. In the ITT Kaplan- Meier/survival analysis, 
participants who are lost to follow- up, or who have Plas-
modium reinfections or inconclusive PCR correction, will 
be censored from the moment of occurrence of one of 
these events. This survival analysis approach is the best 
way of handling missing data because participants with 
partial information are included in the analysis up to the 
time when they are lost/withdraw from the study.
Adverse events
AEs will be graded according to CTCAE V.5.0, November 
2017.
All AEs that are newly started or increased in intensity 
after the study drug administration will be reported. AE 
reports will be generated for all AEs that occurred after 
study drug administration, until the end of the study.
Mathematical modelling
The impact of the ACT AL as prophylaxis for forest goers 
on overall malaria transmission will be quantified using 
mathematical modelling. For this we will develop a popu-
lation dynamic village level individual- based model of 
malaria transmission and treatment parameterised with 
published data, results from the analysis of data from the 
trial and fitted to surveillance data from the study area.
Direct access to source documents/data
Direct access will be granted to authorised representa-
tives from the sponsor and host institution, the regula-
tory authorities, and ethical committee (if applicable), to 
permit trial- related monitoring and inspections.
Quality control and quality assurance procedures
The study will be conducted in accordance with the 
current approved protocol, International Conference on 
Harmonization (ICH) GCP, any national regulations that 
may apply to this study and standard operating proce-
dures. The WorldWide Antimalarial Resistance Network 
(WWARN) will be engaged in assuring quality assurance 
(QA)/quality control (QC) of study execution in collab-
oration with the MORU Clinical Trials Support Group 
(CTSG). Their role will include but not be limited to 
monitoring adherence to standard operating procedures 
(SOPs) for collection of laboratory specimens and quality 
checks (curation) of laboratory data according to stan-
dard methodologies.
Monitoring
Study sites may have in place a system for internal moni-
toring. In addition, regular external monitoring of all 
sites will be performed by the MORU CTSG according 
to ICH GCP and a Monitoring Plan. Data will be evalu-
ated for compliance with the protocol and accuracy in 
relation to source documents. The monitors will check 
whether the clinical trial is conducted and data are gener-
ated, documented and reported in compliance with the 
protocol, GCP and the applicable regulatory require-
ments. Evaluation of on- site monitoring schemes, such as 
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a reciprocal monitoring scheme, may be undertaken at 
selected sites by CTSG.
Patient and public involvement
During 2018, extensive consultations were held with local 
authorities, patients, and study communities regarding 
the design and organisation of the trial. This included the 
district health authorities and Governor’s office. The Siem 
Pang field station conducted malaria treatment studies 
and as part of these studies interviews and questionnaires 
were done with patients to better understand the local risk 
factors for malaria, travel histories and the nature of forest 
work. 23 Specific questions on the time spent in forests24 
and the use of medicines in forests and the willingness to 
take antimalarial prophylaxis were asked. A review of forest 
acquired malaria was prepared at the site in collaboration 
with local partners. 25 The potential importance of antima-
larial prophylaxis was identified through understanding of 
the high risk of malaria infection in local forests and the 
willingness of participants to take medicine to prevent 
this. Through conversations with patients with malaria 
treated at the health centre and from monthly meetings 
with village malaria health workers the design of the study 
was informed. This supported decisions about: time spent 
in forests, follow- up scheduling, type of sample collection, 
monitoring of treatment compliance, suitable locations and 
communities where patients could be enrolled, concerns 
and questions surrounding AEs, and defining the messaging 
and rationale in local languages. Recruitment takes place 
in villages and community leaders and local health workers 
including village malaria workers are part of the study 
team. Patients previously enrolled in studies often serve as 
guides and assistants as they trust the study team and know 
the local community and as they are often forest workers 
themselves they know other forest workers like them who 
may be willing to participate. Conversations were held with 
patients and local stakeholders regarding feasibility and to 
ensure that participation in research would be acceptable 
and not burdensome or interfering with regular activities. 
From these discussions, we adopted an outreach strategy so 
that follow- up can take place without participants needing 
to travel long distances or to the health centres. Dissemina-
tion will take place on several levels: in villages, at district 
level, at provincial level and at a national and international 
level. As part of an ongoing research platform in the district, 
we will communicate results back to study communities at 
the end of the trial by public meetings. A series of public 
engagement activities, including dissemination activities, 




The Investigator will ensure that this study is conducted 
in compliance with the current revision of the Declara-
tion of Helsinki.
ICH guidelines for GCP
The investigators will ensure that this study is conducted 
according to any National Regulations and that it will 
follow the principles of the ICH Guidelines for GCP.
Approvals
The study protocol and its associated documents will 
be submitted to the Oxford Tropical Research Ethics 
Committee and the appropriate local ethics committees 
for written approval.
The investigator will submit and, where necessary, 
obtain approval from the above parties for all substantial 
amendments to the original approved documents.
Risks
This study will use drugs that have been studied thor-
oughly and their toxicities are well described. In general, 
they are all well tolerated. In the event of any serious or 
severe AE participants will be referred to the local referral 
hospital where best available care will be provided.
Risks of AL
The safety of artemether and lumefantrine for treatment 
of malaria has been evaluated in clinical trials and, post 
licensing, widespread use for treating malaria in hundreds 
of millions of patients per year. Reported AL side effects 
have generally been mild. Reported adverse reactions in 
clinical trials have been similar or lower in frequency and 
magnitude to other ACTs. The most common (>=3%) 
reported AEs in clinical studies with AL in adults were 
headache, anorexia, dizziness and asthenia. AL is not 
known to cause harmful prolongation of the corrected 
QT interval (QTc). 27
Risks of multivitamin
The main side- effects of multivitamin are upset stomach, 
unpleasant taste or headache which are mild to moderate 
in nature. Very rarely, these may cause an allergic reaction.
Risk of phlebotomy and finger prick
The primary risks of phlebotomy include local discom-
fort, occasional bleeding or bruising of the skin at the 
site of needle puncture, and rarely haematoma or infec-
tion. Phlebotomy will be performed by suitably qualified 
and trained staff using appropriate hygiene measures 
including gloves and alcohol swabs to clean the skin.
Risk of GPS data
Due to the potential unique nature of the GPS tracking 
data, it may be possible to identify individuals from their 
tracks. This will be minimised by the GPS tracking data 
being kept separately from any personally identifiable 
information and linked to the data collected on the study 
CRF only through a unique study code. The GPS tracking 
data will also be stored anonymously on the tracking 
device during collection and moved to an encrypted hard 
drive on completion of collection.
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Benefits
There are no anticipated direct benefits to the partici-
pants in this study. However, knowledge gained from this 
study is expected to help to assess the efficacy and feasi-
bility of prophylaxis to prevent malaria in forest workers, 
and to predict its efficacy in reducing overall transmis-
sion. The proposed study is a critical step for future use of 
chemoprophylaxis to protect forest workers in the GMS 
against malaria.
Alternatives to study participation
Participants are able to decline freely participation in 
this study. If so, they will receive standard care for their 
malaria (if applicable).
 
Study participants will be compensated for time lost 
from work as a result of trial activities, the cost of local 
transport to attend for the follow- up visits and will receive 
a per diem to cover the costs of meals on those days. The 
amounts in monetary terms will be determined by CNM 
in accordance with local norms.
The study will pay for treatment for drug- related SAEs 
or other research- related injuries. The study cannot pay 
for long- term care for disability resulting from complica-
tions of the illness.
Confidentiality
The trial staff will ensure that the participants’ 
anonymity is maintained. The participants will be iden-
tified only by initials and a study number on the CRF 
and electronic databases. All documents will be stored 
securely and be accessible to trial staff and authorised 
personnel only.
Sample sharing and storage
Samples collected will be used for the purpose of this 
study as stated in the protocol and stored for future use 
no longer than 10 years. Consent will be obtained from 
participants for sample storage and/or shipment of 
specific samples to collaborating institutions for investi-
gations that cannot be performed locally. Any proposed 
plans to use samples other than for those investigations 
detailed in this protocol will be submitted to the rele-
vant ethics committees prior to any testing. Material 
transfer agreements will be arranged and signed where 
appropriate/needed.
Data handling and record keeping
Study data will be recorded on the CRF at the study sites 
and stored in a secure database. Validation checks will be 
built into the study database to identify missing values, 
inconsistencies or invalid data. Additionally, study data 
will be profiled using statistical software to check for 
outliers and errors not detected by the database. All tasks 
related to data management will be carried out in accor-
dance with the study data management plan.
Data sharing
De- identified, individual participant data from this study 
will be available to researchers whose proposed purpose 
of use is approved by the data access committee at 
MORU. Enquiries or requests for the data may be sent to 
datasharing@ tropmedres. ac.
Sponsorship and insurance
The University of Oxford has a specialist insurance policy 
in place: Newline Underwriting Management, at Lloyd’s 
of London—which would operate in the event of any 
participant suffering harm as a result of their involvement 
in the research.
Dissemination plan
Results will be published in the open access peer- reviewed 
medical literature. Any data published will protect the 
identity of the participants. This trial will be registered in 
a web based protocol registration scheme. All those who 
have made a substantial contribution will be coauthors 
on publications. The sites have the right to publish their 
data individually and to include members of the sponsor’s 
team who have made a significant contribution. There 
will also be publications of pooled data which will be coor-
dinated by the MORU group. All sites will have the oppor-
tunity to contribute to these publications.
All the research findings from the programme and 
from relevant research outside the Programme will be 
analysed and integrated, and through the WHO Global 
Malaria Programme will be disseminated to policy makers, 
NMCPs and other researchers.
Standard Protocol Items: Recommendations for Interventional 
Trials checklist
A completed Standard Protocol Items: Recommenda-
tions for Interventional Trials checklist for the protocol is 
provided in online supplemental file 4.
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